EUVIMEDEUVIMED entdecken
Crossref

Vericiguat as a Novel Ferroptosis Inhibitor Alleviates Doxorubicin‐Induced Cardiotoxicity

Huiwen Han, Tao Luo, Canzhao Liu, Wen Ou, Yu Zhang, Zhiyin Zhang, Shuwen Huang, Wenjun Luo, Jiahao Wen, Nan Wang, Ziwei Zhang, Haiqiong Liu und 1 weitere

Basic & Clinical Pharmacology & Toxicology · 2026

DOI: 10.1111/bcpt.70219 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Basic & Clinical Pharmacology & Toxicology, 2026. Verfasst von Huiwen Han und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cardiology, Heart Center, Zhujiang Hospital, Southern Medical University, Guangzhou, Guangdong, China. Hauptthemen laut MEDLINE: Doxorubicin, Ferroptosis, Cardiotoxicity, Cardiomyopathies. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 40 Literaturangaben. Gefördert von: Natural Science Foundation of Guangdong Province, Guangzhou Municipal Science and Technology Bureau, Program of Yunnan Applied Basic Research Project-Kunming Medical University Union Foundation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background and Purpose Doxorubicin is a widely used chemotherapy drug, but its clinical application is limited by dose‐dependent cardiotoxicity, known as doxorubicin‐induced cardiomyopathy (DIC), for which no specific therapies currently exist. Vericiguat, a soluble guanylate cyclase agonist, has shown significant cardiovascular protective effects. However, its role and the underlying molecular mechanisms in DIC remain unclear. Experimental Approach We established both in vivo and in vitro models of DIC. In the in vivo experiments, cardiac function in male wild‐type C57BL/6 mice was evaluated through echocardiography, measurement of serum CK‐MB and cTnT, and histological examinations. For the in vitro studies, cardiomyocyte viability was assessed by CCK‐8 assay and PI/Hoechst staining. To evaluate ferroptosis, the accumulation levels of iron, reactive oxygen species (ROS), and lipid peroxides in cardiomyocytes were assessed using FerroOrange staining, DCFH‐DA fluorescent probe, and MDA content measurement, respectively. The expression levels of ferroptosis‐related markers SLC7A11 and GPX4 were examined by Western blot. Key Results Vericiguat significantly alleviated cardiac injury induced by doxorubicin by lowering oxidative stress and inhibiting ferroptosis and directly counteracted cardiomyocyte injury induced by the ferroptosis activator erastin. Conclusion and Implications These findings indicate that vericiguat protects against doxorubicin‐induced myocardial ferroptosis, positioning it as a promising therapeutic candidate for DIC and a novel ferroptosis inhibitor.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

DoxorubicinFerroptosisCardiotoxicityCardiomyopathiesAnimalsMaleMyocytes, CardiacMice, Inbred C57BLOxidative StressMiceReactive Oxygen SpeciesAntibiotics, AntineoplasticPiperazinesDisease Models, Animal

Stichwörter der Autor:innen

cardiotoxicitydoxorubicinferroptosisoxidative stressvericiguat

Substanzen

DoxorubicinReactive Oxygen SpeciesAntibiotics, AntineoplasticPiperazines

Autor:innen und Institutionen

  • Department of Cardiology, Heart Center, Zhujiang Hospital, Southern Medical University, Guangzhou, Guangdong, China.
  • Guangdong Provincial Biomedical Engineering Technology Research Center for Cardiovascular Disease, Guangzhou, Guangdong, China.
  • Sino-Japanese Cooperation Platform for Translational Research in Heart Failure, Guangzhou, Guangdong, China.
  • Guangdong Provincial Key Laboratory of Shock and Microcirculation, Southern Medical University, Guangzhou, Guangdong, China.
  • Department of Pathophysiology, Zhuhai Campus of Zunyi Medical University, Zhuhai, China.
  • Division of Cardiology, Department of Medicine, School of Medicine, University of California Irvine, Irvine, California, USA.

ORCID-Profile: Xianbao Wang

Förderung

  • Natural Science Foundation of Guangdong Province
  • Guangzhou Municipal Science and Technology Bureau
  • Program of Yunnan Applied Basic Research Project-Kunming Medical University Union Foundation
  • National Natural Science Foundation of China

Zitieren

APA

Han, H., Luo, T., Liu, C., Ou, W., Zhang, Y., Zhang, Z., Huang, S., Luo, W., Wen, J., Wang, N., Zhang, Z., Liu, H., & Wang, X. (2026). Vericiguat as a Novel Ferroptosis Inhibitor Alleviates Doxorubicin‐Induced Cardiotoxicity. Basic & Clinical Pharmacology & Toxicology. https://doi.org/10.1111/bcpt.70219

Vancouver

Han H, Luo T, Liu C, Ou W, Zhang Y, Zhang Z, et al. Vericiguat as a Novel Ferroptosis Inhibitor Alleviates Doxorubicin‐Induced Cardiotoxicity. Basic & Clinical Pharmacology & Toxicology. 2026. doi:10.1111/bcpt.70219

BibTeX
@article{Han2026,
  author = {Han, Huiwen and Luo, Tao and Liu, Canzhao and Ou, Wen and Zhang, Yu and Zhang, Zhiyin and Huang, Shuwen and Luo, Wenjun and Wen, Jiahao and Wang, Nan and Zhang, Ziwei and Liu, Haiqiong and Wang, Xianbao},
  title = {Vericiguat as a Novel Ferroptosis Inhibitor Alleviates Doxorubicin‐Induced Cardiotoxicity},
  journal = {Basic & Clinical Pharmacology & Toxicology},
  year = {2026},
  doi = {10.1111/bcpt.70219}
}
Kostenlos starten →